Professor, Medicine, Perelman School of Medicine
Medical Genetics
Dr. Katherine L. Nathanson, MD
|
|
Give Review
Dr. Katherine L. Nathanson works in the field of Medical Genetics. He went to Perelman School of Medicine at the University of Pennsylvania. He has 3 awards "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification" and "Elected Member". Dr. Katherine L. Nathanson has written publications. He has 35 publications published with PubMed. The lastest paper is: 'DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.' Katherine L. Nathanson, MD accepts all Medicare patients.
Publications
- Multiple gastrointestinal polyps in patients treated with BRAF inhibitors.
- Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.
- Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility.
- Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma.
- A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer.
- Panel testing for inherited susceptibility to breast, ovarian, and colorectal cancer.
- Pathway-based analysis of GWAs data identifies association of sex determination genes with susceptibility to testicular germ cell tumors.
- Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
- Correlation of somatic mutations and clinical outcome in melanoma patients treated with carboplatin, paclitaxel, and sorafenib.
- Two decades after BRCA: setting paradigms in personalized cancer care and prevention.
- Hereditary kidney cancer syndromes.
- Common breast cancer risk variants in the post-COGS era: a comprehensive review.
- Restricted expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Carcinomas enhances HIF2α activity.
- A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.
- Immunotherapy at Large: The road to personalized cancer vaccines.
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma.
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436).
- Meta-analysis identifies four new loci associated with testicular germ cell tumor.
- MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.
- A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry.
- The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling.
- Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
- Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk.
- Inherited Mutations in Pheochromocytoma and Paraganglioma: Why All Patients Should Be Offered Genetic Testing.
- Fine-mapping of Breast Cancer Genome-wide Association Studies Loci in Women of African Ancestry Identifies Novel Susceptibility Markers.
- Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23.
- Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation.
- A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.
- A genome-wide association study of breast cancer in women of African ancestry.
- Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer.
- Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
- DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.
- Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
- Expression of drug targets in patients treated with sorafenib, Carboplatin and Paclitaxel.
Schools
Perelman School of Medicine University of Pennsylvania
Beth Israel Deaconess Med Center
Children39s Hospital Philadelphia
Doctors Specialties
- Clinical Genetics
- Internal Medicine
- Medical Genetics
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Local Value Network EPO
- Local Value Network HMO
- Local Value Network HMO+
- Local Value Network POS+
- Local Value Network PPO
- Personal Choice PPO
- Regional Pref Network EPO
- Regional Pref Network HMO
- Regional Pref Network HMO+
- Regional Pref Network POS+
- Regional Pref Network PPO
- Blue Card PPO
- Capital Blue Cross
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Coventry Health Care
- Coventry Health Care of Delaware PPO
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- HealthPartners
- Community Blue PPO
- Advance EPO
- Direct Access
- Horizon Blue Cross Blue Shield HMO
- Horizon Blue Cross Blue Shield POS
- Horizon Blue Cross Blue Shield PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- Freedom Plan
- QualCare HMO
- QualCare PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- Oxford Liberty
- United Healthcare
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Elected Member
Education
-
Children's Hospital of Philadelphia -
Beth Israel Deaconess Medical Center -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
Hospital of the University of Pennsylvania
Drug Facts
| NPI NUMBER | 1841226024 | |
| NPPES Provider LastName | NATHANSON | |
| NPPES Provider FirstName | KATHERINE | |
| NPPES Provider ZIPCode | 191044306 | |
| NPPES Provider State | PA | |
| Specialty Description | Pediatric Medicine | |
| Total Claim Count | 43.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1841226024 |
| Last Name Of The Provider | NATHANSON |
| First Name Of The Provider | KATHERINE |
| View All |
Similar Doctors
|
|
Dr. Carrie M. Evans, DO
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yuka Furuya, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hakim T. Uqdah, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bolin Niu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carolyn L. Cambor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Esther S. Lee, MD |
|
|
Nancy M. King, LPC |
|
|
Ayala Laufer-Cahana |
|
|
Dr. Nelson A. Wivel, MD |
|
|
Dr. Guy E. McElwain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aleksandr Shpigel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jack S. Nemez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James D. Kolker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard J. Minicozzi, MD |
|
|
Dr. Jeffrey E. Ming, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Carol E. Anderson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew A. Deardorff, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Elaine H. Zackai, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|